Seek Returns

BNTX vs. MEDP: BioNTech vs. Medpace Stock Comparison

How do BioNTech (BNTX) and Medpace (MEDP) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioNTech (BNTX) and Medpace (MEDP) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while MEDP is classified in Life Sciences Tools & Services.

Medpace (MEDP) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BioNTech (BNTX) and Medpace (MEDP)
Profile ItemBNTXMEDP
NameBioNTech SE American Depositary ShareMedpace Holdings, Inc.
Country/RegionGermanyUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization21.70 billion USD18.27 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateOctober 10, 2019August 11, 2016
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

BNTX
MEDP
GSPC
Loading price history…
BioNTech (BNTX) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BioNTech (BNTX) and Medpace (MEDP). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BioNTech (BNTX) and Medpace (MEDP). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
Total Return (1Y)-14.78%13.29%
Total Return (3Y, Annualized)-3.99%35.26%
Total Return (5Y, Annualized)-17.02%24.49%

Risk Profile

Drawdown History

BNTX
MEDP
GSPC
Loading price history…
BioNTech (BNTX) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BioNTech (BNTX) and Medpace (MEDP). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
Volatility (1Y, Annualized)47.44%44.16%
Beta (5Y)1.301.10
Max Drawdown (5Y)-78.10%-42.87%
Avg. Volume (3M)1.21M258.39K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BNTX and MEDP are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
Sharpe Ratio (1Y)-0.400.20
Sortino Ratio (1Y)-0.590.26

Profitability

ROE (TTM)

BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.14%

Max
109.18%
Q3
6.23%
BNTX
-8.14%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP
117.88%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Medpace (MEDP) reports 18.24%, ranking against industry peers normally.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-60.87%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BNTX
-60.87%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP
18.24%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both BioNTech (BNTX) at 30.28% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.28%

Max
83.12%
BNTX
30.28%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max
83.12%
MEDP
23.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
ROE (TTM)-8.14%117.88%
ROA (TTM)-4.04%18.71%
Net Margin (TTM)-60.87%18.24%
Operating Margin (TTM)30.28%23.12%
Gross Margin (TTM)76.73%72.24%

Growth

Revenue Growth

Both BioNTech (BNTX) at 4.32% and Medpace (MEDP) at 19.97% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.

Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
Revenue Growth (YoY)4.32%19.97%
Revenue Growth (3Y CAGR)-45.06%20.12%
EPS Growth (YoY)--20.98%
EPS Growth (3Y CAGR)--28.04%

Financial Strength

Current Ratio (MRQ)

BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.55

Max
25.13
Q3
12.13
BNTX
8.55
Median
5.52
Q1
2.47
Min
0.10

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MEDP
0.83
Min
0.10
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Medpace (MEDP) at 0.29 runs a more typical debt-to-equity mix.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
BNTX
0.02
Min
0.00

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max
1.42
Q3
0.65
MEDP
0.29
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
Current Ratio (MRQ)8.550.83
Debt / Equity (MRQ)0.020.29
Net Debt / EBITDA---0.84

Dividends

Dividend Yield (TTM)

Neither BioNTech (BNTX) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioNTech (BNTX) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BNTX
--

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max
85.34
Q3
43.46
MEDP
36.26
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): BNTX does not report P/E ratio, so it has no value marker; MEDP is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both BioNTech (BNTX) at 8.96 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.96

Max
58.18
Q3
25.77
BNTX
8.96
Median
7.30
Q1
3.01
Min
0.01

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max
58.18
Q3
25.77
Median
7.30
MEDP
6.44
Q1
3.01
Min
0.01
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile relative to book while Medpace (MEDP) at 31.23 prices above its industry range — a wide valuation gap against assets.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BNTX
1.09
Min
-5.59

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP
31.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BioNTech (BNTX) vs. Medpace (MEDP): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioNTech (BNTX) and Medpace (MEDP)
MetricBNTXMEDP
P/E Ratio (TTM)--36.26
P/S Ratio (TTM)8.966.44
P/B Ratio (MRQ)1.0931.23
Free Cash Flow Yield (TTM)-7.34%2.72%